Gennova is a subsidiary of Pune-primarily based pharma firm Emcure Pharmaceuticals. (Representative image)
Biotherapeautics business Gennova Biopharmaceuticals has got approval from the Drugs Controller General of India for conducting Phase I and II human trials for its novel messenger RNA (mRNA)-primarily based Covid-19 vaccine, HGCO19. This is the initial mRNA-primarily based vaccine manufacturing platform in India.
Gennova is a subsidiary of Pune-primarily based pharma firm Emcure Pharmaceuticals. Namita Thappar, ED, Emcure, tweeted on Thursday that Gennova had got conditional approval for human clinical trials of its Covid-19 vaccine. This will also be the initial mRNA-primarily based Covid-19 trial in India and anticipated to be completed by March. The Gennova vaccine was created in collaboration with HDT Biotech Corporation, Seattle, US, and it has demonstrated security, immunogenicity, neutralisation antibody activity in the rodent and non-human primate models. They will be administering the initial human injection soon after all regulatory clearance.
Gennova was 1 of the 3 firms that the Prime Minister, Narendra Modi, interacted with for an update on the improvement of their Covid-19 vaccines. The division of biotechnology has supplied seed funding for Gennova Biopharmaceuticals’s novel mRNA primarily based Covid-19 vaccine candidate referred to as, HGC019.